In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species |
| |
Authors: | N. Miyashita H. Fukano K. Yoshida Y. Niki T. Matsushima |
| |
Affiliation: | (1) Division of Respiratory Diseases, Department of Medicine, Kawasaki Medical School, 577 Matsushima, Kurashiki, Okayama 701-0192, Japan Tel. +81-86-462-1111; Fax +81-86-463-6510 e-mail: nao@med.kawasaki-m.ac.jp, JP |
| |
Abstract: | The in-vitro activity of moxifloxacin, a new fluoroquinolone, against Chlamydia species was investigated. The minimal inhibitory concentration of moxifloxacin for 10 standard strains of different Chlamydia species and 15 wild-type strains of Chlamydia pneumoniae isolated in Japan, which were morphologically different from clinical isolates from the United States, ranged from 0.031 to 0.125 μg/ml. The activity of moxifloxacin was almost the same as those of sparfloxacin, and it was 16, 8, 2, and 2 times more active than ciprofloxacin, levofloxacin, grepafloxacin, and tosufloxacin, respectively. The minimal chlamydiacidal concentration of moxifloxacin ranged from 0.031 to 0.125 μg/ml. These results suggest that moxifloxacin has potential effects against Chlamydia species. Received: August 23, 2001 / Accepted: October 29, 2001 |
| |
Keywords: | Chlamydia species Moxifloxacin Fluoroquinolone Drug susceptibility |
本文献已被 ScienceDirect SpringerLink 等数据库收录! |
|